3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Status
Completed
3
Terminated
1
Sponsor Class
OTHER
4
Study Type
Interventional
4
Sponsor
Cancer Type
CNS
4
Sarcoma
1
Conditions
Glioblastoma
4
Glioma
3
Multiple Myeloma
2
Lymphoma
2
Astrocytoma
2
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Carcinoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Temozolomide
264
Radiotherapy
119
Bevacizumab
105
Magnetic Resonance Spectroscopy
59
Radiation
47
pembrolizumab
30
Irinotecan
28
Surgical Procedures, Operative
23
Lomustine
21
Specimen Handling
19
Nivolumab
19
Radiosurgery
18
Carmustine
18
Aminolevulinic Acid
16
Erlotinib Hydrochloride
15
Drug Therapy
15
Blood Specimen Collection
14
Radiotherapy, Intensity-Modulated
13
O(6)-benzylguanine
13
Chemotherapy, Adjuvant
13
Carboplatin
13
Filgrastim
11
Cyclophosphamide
11
sargramostim
10
poly ICLC
10
atezolizumab
10
Thalidomide
10
Etoposide
10
Ipilimumab
9
Everolimus
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
OTHER
×
Glioblastoma
×
Tetanus Toxoid
×
Clear all
NCT02465268
2025-01-14
ATTAC-II
University of Florida
Phase 2
Completed
175 enrolled
18 charts
NCT00639639
2023-03-13
ATTAC
Duke University
Phase 1
Completed
42 enrolled
NCT02864368
2022-06-09
PERFORMANCE
Duke University
Phase 1
Terminated
27 enrolled
13 charts
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts